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The Three-Fold Axis of the HIV-1 Capsid Lattice Is the
Species-Speciﬁc Binding Interface for TRIM5
Damien Morger,a Franziska Zosel,a Martin Bühlmann,a Sara Züger,a Maximilian Mittelviefhaus,a Benjamin Schuler,a
Jeremy Luban,b Markus G. Grüttera
aDepartment of Biochemistry, University of Zurich, Zurich, Switzerland
bProgram in Molecular Medicine and Department of Biochemistry and Molecular Pharmacology, University of
Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT Rhesus TRIM5 (rhTRIM5) potently restricts replication of human
immunodeﬁciency virus type 1 (HIV-1). Restriction is mediated through direct bind-
ing of the C-terminal B30.2 domain of TRIM5 to the assembled HIV-1 capsid core.
This host-pathogen interaction involves multiple capsid molecules within the hexag-
onal HIV-1 capsid lattice. However, the molecular details of this interaction and the
precise site at which the B30.2 domain binds remain largely unknown. The human
orthologue of TRIM5 (hsTRIM5) fails to block infection by HIV-1 both in vivo and
in vitro. This is thought to be due to differences in binding to the capsid lattice. To
map the species-speciﬁc binding surface on the HIV-1 capsid lattice, we used mi-
croscale thermophoresis and dual-focus ﬂuorescence correlation spectroscopy to
measure binding afﬁnity of rhesus and human TRIM5 B30.2 domains to a series of
HIV-1 capsid variants that mimic distinct capsid arrangements at each of the symme-
try axes of the HIV-1 capsid lattice. These surrogates include previously characterized
capsid oligomers, as well as a novel chemically cross-linked capsid trimer that con-
tains cysteine substitutions near the 3-fold axis of symmetry. The results demon-
strate that TRIM5 binding involves multiple capsid molecules along the 2-fold and
3-fold interfaces between hexamers and indicate that the binding interface at the
3-fold axis contributes to the well-established differences in restriction potency be-
tween TRIM5 orthologues.
IMPORTANCE TRIM5 is a cellular protein that fends off infection by retroviruses
through binding to the viruses’ protein shell surrounding its genetic material. This
shell is composed of several hundred capsid proteins arranged in a honeycomb-like
hexagonal pattern that is conserved across retroviruses. By binding to the complex
lattice formed by multiple capsid proteins, rather than to a single capsid monomer,
TRIM5 restriction activity persists despite the high mutation rate in retroviruses
such as HIV-1. In rhesus monkeys, but not in humans, TRIM5 confers resistance to
HIV-1. By measuring the binding of human and rhesus TRIM5 to a series of engi-
neered HIV-1 capsid mimics of distinct capsid lattice interfaces, we reveal the HIV-1
capsid surface critical for species-speciﬁc binding by TRIM5.
KEYWORDS B30.2, CypA, HIV-1, TRIM5, TRIM5, afﬁnity, binding, capsid, interaction,
species speciﬁcity
The family of tripartite motif-containing (TRIM) proteins encompasses nearly 100members, many of which play important roles in innate immunity and have
antiviral activity. Of the approximately 20 TRIMs identiﬁed to inhibit retroviral infectiv-
ity, TRIM5 imposes the most potent block to retroviral infection (1). The discovery of
TRIM5 as the main restriction factor responsible for the HIV-1 resistance in rhesus
macaques (rhTRIM5) has prompted intensive research efforts, making TRIM5 one of
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the best-studied TRIMs (2, 3). Many of the functional aspects of how TRIM5 acts to
confer resistance to retroviruses can be attributed to its multidomain composition,
characteristic of the tripartite/RBCC motif: an N-terminal RING domain, followed by a
B-box2 domain and a coiled-coil domain (4). The RING domain confers E3 ubiquitin
ligase activity (5), the B-box2 domain mediates self-association important for higher-
order oligomerization (6–8), and the coiled-coil domain causes TRIM to form stable
dimers (9–14).
At the C terminus, TRIM5 contains an additional B30.2 domain. This domain
speciﬁcally recognizes retroviral capsids and deﬁnes the restriction speciﬁcity (15, 16).
Recognition by TRIM5 occurs immediately upon exposure of the retrovirion core to
the target cell cytoplasm at the early postentry stage of retroviral infection (2, 3). The
interaction of the B30.2 domain with the capsid is weak but is potentiated through
avidity effects due to dimerization and higher-order oligomerization of TRIM5 into a
hexagonal lattice that is complementary to the hexagonal arrangement of retroviral
capsids, ideally aligning arrays of B30.2 domains to interact with the repeating binding
sites on the capsid surface (6–8, 17–19). By its speciﬁcity for the common hexagonal
lattice pattern of retroviral capsids, TRIM5 can recognize a broad range of retroviral
cores of highly variable primary structures (11, 20–27). This allows TRIM5 to remain
restrictive despite the high mutation rate of retroviruses. However, the structural basis
for capsid recognition at the crucial step of binding remains elusive.
In TRIM5, the determinants for restriction speciﬁcity are located on four variable
loops, v1 to v4, on the surface of the B30.2 domain. Single nucleotide polymorphisms
within v1 to v4 can change the restriction speciﬁcities of TRIM5 between different
primate populations or species. Unlike some nonhuman primate orthologues, human
TRIM5 (hsTRIM5) only weakly inhibits HIV-1 infection but potently restricts N-tropic
murine leukemia virus (N-MLV) instead (21, 22). A single amino acid substitution from
arginine to proline at position 332 of hsTRIM5 is sufﬁcient to confer the ability to
restrict HIV-1 (28). In some primate species, the B30.2 domain has been replaced by
cyclophilin A (CypA), which binds to the HIV-1 capsid protein via an exposed proline-
rich loop that overlaps with the predicted binding surface of the B30.2 domain (3,
29–33).
Restriction activity of TRIM5 can be blocked in cells by saturation with virus-like
particles bearing properly assembled capsid lattices, but free capsid protein does not
saturate restriction activity in any context (15). This is because signiﬁcant binding of
TRIM5 is detected only with assembled retroviral capsid lattices: TRIM5 has been
shown to associate with capsid cores of virions that have their lipid membrane stripped
off by detergents and in vitro-assembled capsids (8, 9, 15, 18, 19). In contrast, the
interaction with soluble monomeric or dimeric capsid proteins is very weak: the
dissociation constant (Kd) of the rhesus TRIM5 B30.2 domain to a monomeric HIV-1
capsid protein has been estimated to be around 0.4 to 0.5 mM (29, 34). The speciﬁc
sensing of a conserved lattice pattern is noteworthy, as TRIM5 tolerates not only large
variations in capsid sequence but also large differences in the shape of the assembled
capsid: TRIM5 binds both spherical (e.g., N-MLV) and conical (e.g., HIV-1) virions, as
well as in vitro assemblies of capsid or capsid-nucleocapsid forming cylindrical tubes or
even planar two-dimensional lattices (8, 9, 15, 18, 19, 22). The differences in surface
curvature present in those capsid structures are accommodated by changes in the
interhexamer spacing of the capsid lattice, while the hexameric and pentameric
building blocks remain rigid (35). Therefore, it seems surprising that no dramatic
increase in binding afﬁnity was reported for isolated capsid hexamers relative to other
capsid oligomers (34).
Although oligomerization through the B-box and coiled-coil domains greatly con-
tributes to the binding afﬁnity of TRIM5, the monomeric B30.2 domain alone is
sufﬁcient to detectably bind to assembled capsid tubes (34). Atomic resolution struc-
tures of the TRIM5 B30.2 domain reveal that the predicted capsid-binding surface
formed by the variable loops v1 to v4 is larger than the surface presented by one capsid
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subunit in the capsid lattice and suggest that the B30.2 domain binds to a surface area
composed of multiple capsid subunits (34, 36).
In order to identify the binding site of rhTRIM5 on the HIV-1 capsid lattice, we
measured the binding afﬁnity of the TRIM5 B30.2 domain to several isolated capsid
oligomers. Each oligomer mimics a speciﬁc high-symmetry capsid arrangement present
in the hexagonal lattice, as we reasoned that B30.2 binding to these sites will allow the
assembly of the complementary hexagonal TRIM5 lattice. We produced the full-length
HIV-1 capsid protein, which forms dimers in solution, the monomeric capsid N-terminal
domain (NTD), and a disulﬁde-stabilized capsid hexamer (37–39). To complete the
collection of isolated HIV-1 capsid lattice mimics, we designed mutations that allow the
production of a trimeric capsid surrogate that is cross-linked at the 3-fold symmetry axis
of the lattice, reﬂecting the common interface between three adjacent hexamers.
Furthermore, by comparing the binding afﬁnities of the B30.2 domains of rhTRIM5
and hsTRIM5 to these HIV-1 capsid surrogates, we reveal distinct contributions of the
mimicked capsid arrangements to the overall afﬁnity and speciﬁcity of the restriction
factor for the HIV-1 capsid lattice.
RESULTS
Design and production of a trimeric HIV-1 capsid that mimics the 3-fold
interface on the HIV-1 capsid lattice. In order to characterize binding of TRIM5 to
the retroviral capsid surface, we produced oligomeric HIV-1 capsid molecules that
mimic distinct capsid arrangements of the assembled HIV-1 capsid lattice (Fig. 1a): the
wild-type, full-length HIV-1 capsid protein which forms dimers in solution (capsid
dimer) (37), the monomeric HIV-1 capsid N-terminal domain (NTD) without the
C-terminal dimerization domain (CTD) (capsid monomer), the disulﬁde-stabilized
hexameric capsid (capsid hexamer) as described by Pornillos et al. (38), and a trimeric
HIV-1 capsid that resembles an arrangement around the 3-fold axis of the capsid lattice
(Fig. 1b). The interface at the 3-fold axis is formed by six capsid molecules: three of
them form a trimeric contact via the CTDs, and the other three come into proximity at
their NTDs. The proximal capsid NTDs form a surface that is accessible to TRIM5 binding,
while the capsid CTDs are located on the inside of the HIV-1 capsid core.
To design mutations that allow cross-linking of the capsid NTDs at the 3-fold lattice
interface, available models (described below) of the assembled HIV-1 capsid shell were
FIG 1 HIV-1 capsid lattice and oligomeric HIV-1 capsid surrogates that mimic distinct arrangements
within the lattice. Models were generated by aligning the high-resolution structures of the HIV-1 capsid
N-terminal domain (capsid NTD; PDB entry 1AK4) and the capsid C-terminal domain (capsid CTD; PDB
entry 1A8O) into the low-resolution structure of two-dimensional capsid arrays (PDB entry 3DIK). (a)
Excerpt of the hexagonal HIV-1 capsid lattice as represented by three neighboring hexamers. The 2-fold,
3-fold, and 6-fold symmetry axes of the lattice are indicated by red ellipses, triangles, and hexagons,
respectively. The capsid NTDs are colored alternating in blue and green, and the capsid CTDs are shown
in gray. (b) Models of oligomeric HIV-1 capsid surrogates used in this study to mimic distinct capsid
arrangements at individual symmetry axes of the assembled HIV-1 capsid: the monomeric capsid NTD
(monomer), the dimeric full-length wild-type capsid (dimer), the disulﬁde-stabilized hexameric capsid
(hexamer), and the novel chemically cross-linked trimeric capsid (trimer).
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inspected for residues that come into proximity. These models revealed that residues
within -helix 4 have the closest distance between three adjacent capsid NTDs (Fig. 2a
and b). However, according to the most recent model of the mature HIV-1 capsid (35)
(PDB entry 3J34), these residues are located roughly 20 Å apart. This is too far for
chemical cross-linking with commercially available trifunctional cross-linkers (Fig. 2c).
However, this is not the case when the structure of a planar HIV-1 capsid lattice derived
from two-dimensional capsid arrays is considered (40). There, the NTDs come closer
together at the trimer interface due to the lack of curvature in the 2D lattice (PDB
entry 3DIK). Also, TRIM5 is known to bind a broad range of retroviruses harboring
different capsid curvatures, including planar hexagonal arrays formed by HIV-1 capsid-
nucleocapsid mutants (18). Therefore, we considered the HIV-1 capsid lattice structure
derived from planar two-dimensional (2D) capsid crystals a valuable model to design
potential TRIM5-binding capsid oligomers. By aligning the crystal structure of the HIV-1
capsid NTD (PDB entry 1AK4) onto the cryo-electron microscopy (cryo-EM)-based 9-Å
model of the planar lattice (PDB entry 3DIK) using PyMOL (33, 40), we estimated the
FIG 2 Cysteine mutations in the HIV-1 capsid NTD designed for cross-linking the 3-fold lattice interface. (a and b) Model
of the trimeric lattice interface formed by the HIV-1 capsid NTDs, obtained by superimposing the high-resolution structure
of the HIV-1 capsid NTD (cyan; PDB entry 1AK4) onto the cryo-EM-based model of planar HIV-1 capsid arrays (PDB entry
3DIK). Residues in close proximity between NTDs at the 3-fold axis were selected for mutagenesis to cysteines. Interdomain
distances (in Å) between introduced cysteines (in cyan) in -helix 4 and the CypA binding loop are indicated with yellow
dashed lines. (a) Top view onto the 3-fold lattice interface formed by the capsid NTDs. (b) Side view of two NTDs in the
3-fold lattice interface. (c) The trifunctional maleimide TMEA with spacer arm distances of 10.3 Å used to cross-link the
NTD-trimer interfaces via engineered cysteines. (d) SDS-PAGE analysis of in vitro-assembled HIV-1 capsid mutants
chemically cross-linked with equimolar amounts of TMEA. Monomeric (1 capsid), dimeric (2 capsids), and trimeric (3
capsids) cross-linking products are indicated. The supernatant and pellet after centrifugation conﬁrm that capsid trimers
only form in the assembled capsid fraction, as shown for the mutants with the highest cross-linking efﬁciency (destabilized
R82C and P85C mutants). Molecular mass standards in kilodaltons are indicated to the left of the Coomassie blue-stained
SDS gels.
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closest distances to be 10 Å for residues R82 and P85 (Fig. 2a and b). This distance
matches the requirements for cross-linking three neighboring capsid proteins with the
trifunctional cross-linker TMEA [tris(2-maleimidoethyl)amine] (Fig. 2c). Residues E75,
A78, and E79 along -helix 4 were chosen as well for mutation to cysteines (Fig. 2b).
Because TMEA cross-linking is performed on the assembled HIV-1 capsid, where all
lattice contacts are formed, additional destabilizing mutations were introduced to
facilitate subsequent disassembly of the cross-linked capsid lattice. Two sets of muta-
tions, W184A M185A and E180D V181A, were tested to destabilize the dimerization
interface in the capsid CTD (38, 41, 42).
To test the ability of these mutants to form the relevant lattice interfaces, recom-
binant capsid proteins were puriﬁed and tested for their ability to assemble in vitro by
dialysis against 1 M sodium chloride at protein concentrations of 10 mg/ml. All capsid
mutants, except for the ones harboring W184A M185A mutations in the CTD region,
turned turbid, indicative of capsid assembly. Further analysis of the in vitro-assembled
HIV-1 capsid variants by negative-staining EM revealed that cysteine mutants without
destabilizing mutations formed elongated tubes, as observed for the wild-type capsid
protein, while cysteine mutants combined with the destabilizing E180D V181A muta-
tions formed both elongated tubes and planar sheets (Fig. 3a and b). The Fourier
transform of negative-staining EM images conﬁrms that these planar sheet structures
are hexagonal arrays of assembled capsid molecules (Fig. 3a, inset). As outlined above,
the planar geometry brings the introduced cysteines closer together, which increases
cross-linking efﬁciency. Short incubation of the assembled capsid with equimolar
concentrations of TMEA and subsequent disassembly yielded capsid oligomers coupled
to only one TMEA molecule. Under these conditions, the R82C and P85C mutants with
predicted distances of 10 Å cross-linked more efﬁciently to trimers than the other
mutants with more distantly positioned cysteines (Fig. 2d). Separation of assembled
capsids and soluble capsid proteins was done by centrifugation. Cross-linked trimers
were found only in the pellet fraction, conﬁrming that cross-linking of trimer interfaces
occurs only in the hexagonal capsid lattice (Fig. 2d).
Of the R82C and P85C mutants, which cross-linked more efﬁciently to trimers, we
focused on the R82C mutation for further puriﬁcation and characterization, because
modifying P85 in the exposed cyclophilin A binding loop might impair TRIM5 binding
(33). Thorough biophysical characterization of the ﬁnal TMEA cross-linked product
(R82C E180D V181D) puriﬁed from cross-linked and then disassembled capsid con-
ﬁrmed that it is a trimer in solution (Fig. 3).
Binding afﬁnity of TRIM5 to the capsid dimer does not correlate with restric-
tion speciﬁcity. To measure binding afﬁnities, we used microscale thermophoresis
(MST) and dual-focus ﬂuorescence correlation spectroscopy (2fFCS). The B30.2 domains
from TRIM5 and its TRIM20 homolog were ﬂuorescently labeled and titrated with
increasing concentrations of unlabeled capsid molecules (see Fig. 4 for SDS analysis of
the puriﬁed constructs). For determination of afﬁnities in the micromolar range,
ﬂuorescence-based methods have the advantage that one reaction partner can be kept
constant at a very low (nanomolar) concentration. Thus, the titration can be described
with the simple binding isotherm equation fb  [capsid]/Kd  [capsid], facilitating the
comparison of results (fb is the fraction of bound B30.2 domain, [capsid] is the capsid
concentration, and Kd is the dissociation constant). All Kds reported in this work refer to
the concentration of monomeric capsid equivalents to facilitate comparison between
the individual values.
By MST, migration of a ﬂuorescently labeled protein is measured along a temper-
ature gradient as a function of a titrated unlabeled binding partner to determine
binding afﬁnities. This method is not affected by the increased viscosity at high capsid
protein concentrations, as it measures interactions via changes in the equilibrium
distribution of the concentration (43). We performed MST measurements with the
wild-type HIV-1 capsid dimer and homologous TRIM B30.2 domains. The rhTRIM5
B30.2 domain has the strongest afﬁnity for the wild-type HIV-1 capsid dimer, in
comparison to other capsid molecules reported so far (29). The measurements revealed
TRIM5 Binding to Interfaces of the HIV-1 Capsid Journal of Virology
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a Kd of 0.62  0.04 mM for binding of the rhTRIM5 B30.2 domain to the capsid dimer.
The B30.2 domain of TRIM20/pyrin, which has no restriction activity against retroviruses
(1), was used as a negative control and exhibited a signiﬁcantly weaker Kd of 1.8  0.1
mM for the capsid dimer (Fig. 5b).
All measurements were conducted at 280 K because of aggregation of highly
concentrated capsid surrogate solutions at higher temperatures. We ruled out a large
inﬂuence of temperature on the binding afﬁnity by comparing measurements at 280
and 295 K, which yielded very similar Kds (0.64  0.06 mM at 295 K) for binding of the
rhTRIM5 B30.2 domain to the capsid dimer (Fig. 6a).
FIG 3 Production and biophysical characterization of the TMEA-cross-linked R82C E180D V181A capsid
trimer. (a and b) Assemblies of HIV-1 capsid cysteine mutants that mimic the HIV-1 capsid surface and
enable cross-linking of NTD-trimer interfaces. (a) Representative negative-staining EM image of in
vitro-assembled R82C E180D V181A HIV-1 capsid. Assembly products form both elongated tubes, as seen
on the bottom left (indicated by arrows), and planar sheets. One sheet is shown in the center of the
micrograph. The scale bar corresponds to 1 m. The hexagonal order of capsid molecules within an
assembled HIV-1 capsid sheet is shown by a representative Fourier transform of a sheet image (inset). (b)
Negative-staining EM image of in vitro-assembled R82C HIV-1 capsid lacking lattice-destabilizing muta-
tions. This mutant forms elongated tubes only, as would be the case for the wild-type HIV-1 capsid (52).
The scale bar corresponds to 1 m. (c) Size exclusion chromatography (SEC) proﬁle of the capsid trimer
after disassembly of TMEA cross-linked R82C capsid lattices, with elution volumes of protein standards
indicated on top of the panel. The SDS-PAGE analysis of 7-ml peak fractions indicated by the bar below
the chromatography proﬁle shows the high purity of the monodispersely eluting capsid trimer. The
ESI-MS spectrum (d) and the sedimentation velocity analytical ultracentrifugation analysis (e) are
consistent with the calculated mass of 76,866.3 Da for the HIV-1 capsid trimer. k, thousand.
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To see if the Kds measured by MST correlate with the species-speciﬁc differences in
HIV-1 restriction activity, we also measured binding of the capsid dimer to the B30.2
domain of hsTRIM5. Unexpectedly, hsTRIM5 B30.2 had a slightly higher afﬁnity for
the capsid dimer (Kd  0.49  0.06 mM) than its primate orthologue (Fig. 5b). It thus
appears that the binding afﬁnities toward the capsid dimer do not correlate with the
in vivo HIV-1 restriction speciﬁcities of the two TRIM5 orthologues, suggesting that
species speciﬁcity is determined by B30.2 binding to other capsid surfaces.
To determine whether capsid dimerization via the CTDs contributes to the afﬁnity
for the B30.2 domain, we performed MST measurements with the monomeric capsid
NTD (capsid monomer). A very weak Kd of 1.6  0.1 mM was determined for the
rhTRIM5 B30.2 domain, which is similar to the Kd of 2.2  0.1 mM obtained for the
TRIM20 negative control (Fig. 5a). In addition, when lysozyme was used as a control for
unspeciﬁc binding to rhTRIM5 B30.2, ﬁtting of the apparent binding curve resulted in
a Kd of 2.6  0.3 mM, which is in a similar range as that for the TRIM20 control (Fig. 5e;
Table 1). Compared to the binding afﬁnity of 0.62 mM per binding site for the capsid
dimer (Fig. 5e; Table 1), the almost 3-fold lower afﬁnity for the capsid monomer
conﬁrms the contribution of capsid dimerization to rhTRIM5 B30.2 binding previously
reported by nuclear magnetic resonance (NMR) (29). Again, MST measurements of the
capsid monomer interaction with hsTRIM5 B30.2 revealed a slightly higher afﬁnity (Kd
of 1.1  0.1 mM) than that for the rhesus orthologue (Fig. 5a and f).
To verify these rather low determined afﬁnities and because other capsid surrogates
than the capsid monomer and dimer could not be measured by MST, we performed
independent measurements of the interaction between the B30.2 domain of rhTRIM5
and the capsid dimer by 2fFCS. With 2fFCS, binding afﬁnities are determined by
measuring the diffusion time of a ﬂuorescently labeled protein whose hydrodynamic
radius (Rh) increases upon binding as a function of the concentration of the unlabeled
binding partner (44). Since increasing solution viscosity at high capsid protein concen-
trations contributes to the binding-dependent change in diffusion time, human cyclo-
philin A (CypA) was measured as a reference in an independent experiment to correct
for viscosity effects as described in Materials and Methods. CypA binds to the capsid
surrogates with a much higher afﬁnity (Kd  16 M) (45) than rhTRIM5, allowing us
to separate the contributions of binding and viscosity to the change in Rh (Fig. 7a).
FIG 4 SDS-PAGE analysis of puriﬁed HIV-1 capsid molecules and ﬂuorescently labeled capsid binding
domains. (a) Nonreducing SDS-PAGE of puriﬁed HIV-1 capsid molecules. The capsid monomer (capsid
NTD), the capsid dimer (wild-type, full-length capsid protein), the capsid trimer (full-length capsid
proteins cross-linked via the NTDs), and the capsid hexamer (disulﬁde-linked full-length capsid proteins)
show the expected relative increases in molecular mass. Note that the capsid dimer is dissociated into
its two full-length subunits. (b) Reducing SDS-PAGE of puriﬁed and Alexa 488-labeled capsid-binding
domains: the Flag-tagged CypA, the B30.2 domain of hsTRIM5, and the B30.2 domain of rhTRIM5. (a
and b) Molecular mass standards in kilodaltons are indicated to the left of the Coomassie blue-stained
SDS gels.
TRIM5 Binding to Interfaces of the HIV-1 Capsid Journal of Virology
March 2018 Volume 92 Issue 5 e01541-17 jvi.asm.org 7
 o
n
 June 12, 2018 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
In the absence of capsid protein, we measured an Rh of 3.2  0.1 nm for the
rhTRIM5 B30.2 domain, which increases to 5.4  0.1 nm (Fig. 7d) when the capsid
dimer is bound. The Kd of this interaction is 0.60  0.07 mM, which matches the Kd
obtained by MST (Fig. 6b; Table 1).
Species speciﬁcity of TRIM5 binding to the capsid trimer. We next probed the
interaction of the HIV-1 capsid trimer and hexamer with the TRIM5 B30.2 domains. The
capsid hexamer recapitulates capsid interfaces at the 6-fold axis of the hexagonal
lattice, and the capsid trimer reﬂects the common interface between three adjacent
hexamers (Fig. 1). Since both capsid oligomers could not be measured to high enough
concentrations by MST due to aggregation caused by the temperature gradient, we
used 2fFCS as described for the capsid dimer to determine the binding afﬁnities. We
obtained Rh values of 5.6 nm and 7 nm for the capsid trimer- and the capsid
hexamer-B30.2 complexes, respectively (Fig. 7b to d).
FIG 5 Binding measurements of TRIM B30.2 domains interacting with surrogates of the HIV-1 capsid lattice. The
capsid concentrations are plotted as concentrations of monomeric capsid equivalents. All binding curves were
ﬁtted with a 1:1 binding isotherm to obtain the dissociation constant, Kd (Table 1). (a and b) Comparison of the
binding curves obtained from MST measurements of rhTRIM5, hsTRIM5, and hsTRIM20 B30.2 domains titrated
with the capsid monomer (a) and dimer (b). (c and d) Measurements of capsid trimer (c) and hexamer (d) binding
to the B30.2 domains of rhTRIM5 and hsTRIM5 by 2fFCS. For determination of the dissociation constants (Kd),
CypA was used as a reference to correct for the viscosity increase at high capsid surrogate concentrations (see
Materials and Methods). (e and f) Comparison of binding curves obtained from MST and 2fFCS measurements for
the B30.2 domains of rhTRIM5 (e) and hsTRIM5 (f). The titration of lysozyme to the B30.2 domain of rhTRIM5
is shown in gray and is representative of an unspeciﬁc interaction. The titration curve for the capsid hexamer is
omitted for clarity.
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The Kd of the capsid hexamer for the B30.2 domain of rhTRIM5 was 0.60 0.09 mM
(Fig. 5d), showing that the capsid hexamer has an increased afﬁnity for the rhTRIM5
B30.2 domain compared to the monomeric capsid NTD, but not compared to the
capsid dimer (Table 1). To investigate if binding to the capsid hexamer accounts for the
difference in HIV-1 restriction activity between hsTRIM5 and rhTRIM5, we measured
the interaction with the B30.2 domain of hsTRIM5. However, these measurements
revealed an afﬁnity of 0.54  0.1 mM, which is within error identical to the Kd found for
rhTRIM5 B30.2 (Fig. 5d and f; Table 1). We note that the data for the capsid hexamer
did not perfectly ﬁt the simple one-to-one binding model, as was the case for the other
capsid surrogates (Fig. 5d). Possible reasons include the presence of an additional
binding mode for the B30.2 domain or further oligomerization of the hexamer at higher
concentrations.
Binding of the B30.2 domain of rhTRIM5 to the capsid trimer had a Kd of 0.44 
0.04 mM (Fig. 5c). Thus, the capsid trimer shows the strongest increase in afﬁnity
relative to the monomeric capsid NTD among the capsid surrogates investigated (Table
1; Fig. 5e). In contrast, measurement of the interaction with hsTRIM5 B30.2 revealed
a signiﬁcantly lower afﬁnity, with a Kd of 0.84  0.09 mM for the capsid trimer (Fig. 5c
and e; Table 1). The afﬁnity difference of the B30.2 domains of hsTRIM5 and rhTRIM5
for the capsid trimer correlates with the species-speciﬁc difference in restriction activity
FIG 6 rhTRIM5 B30.2 binding to the capsid dimer measured at different temperatures and with different methods.
(a) MST measurements performed at 295 K. Error bars indicate the standard deviation of three independent
measurements. Fitting the data with equation 1 (black line) yields a Kd of 0.64  0.06 mM, within error of the Kd
obtained at 280 K. (a) Overlay of 2fFCS and MST measurements at 295 K. The MST data are ﬁtted with equation 1
(solid line); error bars indicate the standard deviation of three independent measurements. For determining the Kd
by 2fFCS, CypA was used as a reference to correct for viscosity effects at increased capsid protein concentrations
(see Materials and Methods). The 2fFCS data were converted to fraction bound with equation 3 and are shown with
a 1:1 binding isotherm (solid line), calculated using the Kd from a ﬁt with equation 2. MST and 2fFCS yield consistent
binding curves with Kd values of 0.62  0.04 mM (MST) and 0.60  0.07 mM (2fFCS).
TABLE 1 Overview of dissociation constants measured by MST and 2fFCS for the
interaction of TRIM B30.2 domains and CypA with the different HIV-1 capsid surrogates
normalized to monomeric capsid equivalents
Capsid surrogate
or negative control
Kda
rhTRIM5 hsTRIM5 hsTRIM20 CypA
Capsid monomer 1.6 0.1 mMb 1.1 0.1 mMb 2.2 0.1 mMb ND
Capsid dimer 0.61 0.04 mMd 0.49 0.06 mMb 1.8 0.1 mMb 26.5 5 Mc
Capsid trimer 0.44  0.04 mMc 0.84  0.09 mMc ND 17.8 2 Mc
Capsid hexamer 0.60 0.09 mMc 0.54 0.1 mMc ND 28.9 3 Mc
Lysozyme 2.6 0.3 mMc ND ND ND
aThe Kds for the interactions of TRIM B30.2 domains with the different HIV-1 capsid surrogates, as well as
lysozyme, are indicated relative to the concentrations of the monomeric capsid equivalents. The Kds of the
rhTRIM5 and hsTRIM5 B30.2 domains for the capsid trimer, which has the strongest binding afﬁnity for
the B30.2 domain of rhTRIM5 as well as the greatest increase in afﬁnity compared to the Kd for the B30.2
domain of hsTRIM5, are highlighted in bold. ND, not determined.
bKd determined by MST.
cKd determined by 2fFCS.
dAverage of Kds determined by MST and 2fFCS.
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against HIV-1 and suggests that determinants for species-speciﬁc recognition by
TRIM5 are located at the 3-fold lattice interface of the HIV-1 capsid.
DISCUSSION
The capsid molecules described in this study mimic different surface areas on the
assembled HIV-1 capsid core. All together, they represent all high-symmetry capsid
arrangements on the hexagonal lattice. To determine the potential binding site of
TRIM5, we measured the binding afﬁnities between these capsid surrogates and
the B30.2 domains of rhTRIM5 and hsTRIM5. A detailed knowledge of this binary
interaction is essential for understanding the overall binding capability of TRIM5 to
the HIV-1 capsid lattice, but the experimental determination of the very high dissoci-
ation constants poses a technical challenge. We measured these low afﬁnities with two
ﬂuorescence-based methods, MST and 2fFCS. Thus, we could employ low concentra-
tions of one titrant (the ﬂuorescently labeled B30.2 domains), enabling the use of a
ﬁrst-order binding model to ﬁt the data.
MST measurements revealed a Kd of around 0.6 mM for binding of the rhTRIM5
B30.2 domain to the capsid dimer, which was conﬁrmed by 2fFCS (Fig. 5a). This
interaction is clearly distinguishable from the negative controls and the Kd for the
capsid monomer (Fig. 5; Table 1). This observation agrees with previous ﬁndings from
NMR studies: the interaction with the capsid monomer is very weak, and dimerization
of the capsid via the CTD greatly enhances the afﬁnity for the B30.2 domain of
rhTRIM5 (29, 34). We also found that relative to the capsid monomer, the afﬁnity of the
capsid dimer and hexamer for the B30.2 domain of rhTRIM5 is similarly increased (Kd
values of 0.62 and 0.60 mM, respectively) (Table 1). Strikingly, the capsid trimer, which
has never been investigated before, had the highest afﬁnity for the B30.2 domain of
rhTRIM5, with a Kd of about 0.44 mM per capsid subunit (Fig. 5c and e; Table 1).
FIG 7 The hydrodynamic radius, Rh, of rhTRIM5 B30.2 and CypA as a function of the concentration of HIV-1 capsid
surrogates. Rh, as determined by 2fFCS (see Materials and Methods), is plotted against the concentration of capsid
dimer (a), trimer (b), and hexamer (c). Insets show concentrations of up to 0.2 mM capsid monomer equivalents to
highlight the difference between B30.2 and CypA binding. The data are ﬁtted with equation 2 (solid lines). For
CypA, the two processes contributing to an increase of Rh (capsid binding and viscosity increase) occur over
well-separated capsid concentration ranges, allowing the reliable determination of Rh of the CypA-capsid complex
and the capsid concentration-dependent increase in viscosity (see Materials and Methods). (d) Rh values deter-
mined for rhTRIM5 B30.2, CypA, and the rhTRIM5/CypA-capsid complexes. Error bars indicate the standard
deviation of three independent measurements. The Rh values of CypA and rhTRIM5 B30.2 are identical within
error, justifying the assumptions described in Materials and Methods. The hydrodynamic radii of the rhTRIM5
B30.2-capsid surrogate complexes are assumed to be identical to those of the respective CypA-capsid surrogate
complexes.
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In order to investigate if one of these HIV-1 capsid surrogates mimics a lattice
surface area that accounts for species-speciﬁc restriction by TRIM5, we also measured
the binding afﬁnities of the hsTRIM5 B30.2 domain. We found that the capsid
monomer, dimer, and hexamer all had a similar or slightly stronger afﬁnity for the
human orthologue (Fig. 5; Table 1). However, the capsid trimer had a signiﬁcantly
weaker afﬁnity for the hsTRIM5 B30.2 domain than its rhesus orthologue (Kds of 0.44
mM and 0.84 mM, respectively) (Fig. 5c; Table 1). Based on this Kd difference, we
conclude that the capsid trimer harbors the binding surface area that contributes to the
species-speciﬁc restriction potency of TRIM5 against HIV-1. The 2-fold increase in
afﬁnity between monomeric B30.2 domains for the 3-fold capsid lattice interface is
expected to be potentiated through avidity effects in the context of HIV-1 restriction in
vivo: the weak B30.2-capsid interactions are ampliﬁed, as TRIM5 self-assembles into a
hexagonal superlattice matching the geometry of the assembled HIV-1 capsid, thereby
ideally positioning many B30.2 domains to their repeating binding sites on the HIV-1
capsid lattice (6–9, 11, 18, 19, 36, 46). Therefore, small differences in afﬁnity between
different B30.2 domains will be translated into large differences in the overall binding
capability of TRIM5, which could deﬁne the restriction potency of the different protein
variants. It is possible that the R82C mutation in -helix 4 of the capsid trimer impairs
B30.2 binding by inﬂuencing the capsid surface region near the CypA binding loop,
explaining the weak afﬁnities determined with the capsid trimer. Nevertheless, CypA
binding to the capsid trimer was not weakened compared to the binding to the
wild-type capsid dimer (Table 1), and we found that rhesus TRIM5 B30.2 binding to the
capsid trimer was not just retained but was even stronger than the afﬁnities measured
with the other HIV-1 capsid surrogates.
Our data suggest that TRIM5 binds to an overlapping surface area shared among
the capsid dimer, trimer, and hexamer, involving multiple capsid molecules. Such
capsid arrangements are found at the interhexamer interfaces of the HIV-1 capsid
lattice. Binding of TRIM5 to this region would be in line with the mapping of residues
involved in TRIM5 binding to the outer edges of the capsid hexamer (26, 29–32) (Fig.
8a). On the B30.2 domain, capsid binding is predicted to be mediated by four variable
loop regions, v1 to v4 (29, 47, 48). Recent atomic resolution structures of the TRIM5
B30.2 domain have shown that these loop regions form a continuous surface, large
enough to cover three or four capsid molecules (34, 36). Hot spots of positive selection
through primate evolution and residues most affected by capsid binding in NMR
studies cluster in the v1 loop of the B30.2 domain of rhTRIM5 (47, 49). Also, the single
FIG 8 Model of the B30.2–HIV-1 capsid interaction. (a) Mapping of mutations on the HIV-1 capsid lattice
that allow the virus to escape restriction by rhTRIM5. These hot spot residues, predicted to be involved
in the interaction with TRIM5, are shown in red. (b) Model of the B30.2–HIV-1 capsid interaction that
matches the binding data and involves the hot spot residues. The position corresponding to proline 332
in rhTRIM5, which determines the species speciﬁcity of restriction compared to hsTRIM5, is indicated
by a blue star on the v1 loop of the B30.2 domain and is placed such that the v1 loop binds to the trimer
interface of the capsid lattice. The rest of the B30.2 domain of rhTRIM5, involving loops v2 to v4, is
located such that it binds to the interface between two neighboring capsid hexamers. This interface
combines the surface areas mimicked by the capsid dimer, the capsid trimer, and the capsid hexamer,
matching the increased afﬁnities measured for all oligomeric capsid arrangements compared to that of
the capsid monomer.
TRIM5 Binding to Interfaces of the HIV-1 Capsid Journal of Virology
March 2018 Volume 92 Issue 5 e01541-17 jvi.asm.org 11
 o
n
 June 12, 2018 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
arginine-to-proline mutation that switches the restriction activity of hsTRIM5 toward
HIV-1 is located on the v1 loop (28). Based on our binding results, we propose a model
for the interaction of the B30.2 domain of rhTRIM5 with the HIV-1 capsid lattice that
involves these known binding determinants of TRIM5. The B30.2 v1 loop and the
capsid trimer interface are the dominating determinants for both afﬁnity and speciﬁcity
in the TRIM5 capsid interaction. Therefore, we suggest that the B30.2 v1 loop region
binds near the 3-fold symmetry axis between three adjacent capsid hexamers of the
HIV-1 capsid lattice. By positioning the remaining predicted binding surface of the
B30.2 domain, involving the v2, v3, and v4 loops, at the 2-fold symmetry axis between
two neighboring hexamers, we match the increased afﬁnity observed for all the
oligomeric capsids tested, as this interface combines capsid arrangements mimicked by
the capsid dimer, trimer, and hexamer (Fig. 8b). A very similar binding model has been
predicted by computational docking of the B30.2 domain to the HIV-1 capsid (50).
In the TRIM5 variant TRIMCyp, which confers HIV-1 resistance, for example, in owl
monkeys, the C-terminal B30.2 domain has been replaced by a CypA domain (3). A
binding model where the CypA domain preferentially binds at the 3-fold symmetry
interface of the HIV-1 capsid lattice is also suggested by our data: as for the B30.2
domain of rhTRIM5, we found that CypA has a higher average binding afﬁnity per
capsid subunit for the capsid trimer than for the other capsid molecules (Table 1). This
is likely the case because the CypA binding loops on the HIV-1 capsids come together
at the 3-fold symmetry axis, while in the dimer and hexamer they are pointing away
from each other. Preferential binding of the CypA domain to the 3-fold capsid sym-
metry interfaces, as we propose for the B30.2 domain of TRIM5, would allow TRIMCyp
to match the same geometrical criteria to bind and form a complementary superlattice
on the retroviral capsid as TRIM5.
In conclusion, we present a novel chemically cross-linked HIV-1 capsid trimer that
recapitulates the capsid arrangement at the 3-fold symmetry axis on the outward-
facing side of the assembled HIV-1 capsid lattice. Its potential as a tool for character-
izing HIV-1 capsid binding molecules is exempliﬁed in this study. The binding mea-
surements with orthologous TRIM5 B30.2 domains reveal that this capsid trimer has
a stronger afﬁnity for rhTRIM5 than other capsid oligomers that mimic capsid arrange-
ments on the HIV-1 lattice. Of the monomeric, dimeric, trimeric, and hexameric capsids
measured, only the binding afﬁnities of the capsid trimer to the human and rhesus
B30.2 domains correlate with their respective HIV-1 restriction activities. Based on our
results, we propose a binding model that explains how a single point mutation in the
v1 loop of the B30.2 domain is sufﬁcient to confer HIV-1 restriction activity to the
otherwise unrestrictive hsTRIM5.
MATERIALS AND METHODS
Design and production of cross-linked HIV-1 capsid trimers. The DNA sequence encoding amino
acids 133 to 363 of the HIV-1 Gag polyprotein was ampliﬁed from psPAX2 (51) and cloned into a pET-20b
vector (Invitrogen). Mutations were introduced by QuikChange mutagenesis (Invitrogen) and veriﬁed by
DNA sequencing (Microsynth). The HIV-1 capsid proteins were expressed and puriﬁed as previously
described (45), with the addition of 100 mM -mercaptoethanol (ME) to all buffers. Capsid tubes were
assembled in vitro by overnight dialysis at 4°C (52) into assembly buffer (20 mM Tris-HCl, pH 8, 1 M NaCl,
100 mM ME).
For cross-linking of assembled capsid tubes harboring mutations E75C, A78C, E79C, R82C, or P85C in
their NTD combined with or without destabilizing E180D V181A mutations in the CTD, the initial
assembly buffer was exchanged against cross-linking buffer [20 mM HEPES-HCl, pH 7.2, 1 M NaCl, 0.5 mM
Tris(2-carboxyethyl)phosphine (TCEP)] by a two-step dialysis. Chemical cross-linking of neighboring NTDs
via the introduced cysteines was performed at a concentration of 10 mg/ml capsid protein by incubation
with the trifunctional maleimide cross-linker TMEA (Thermo Scientiﬁc) at a 1:1 molar ratio of TMEA to
capsid monomer for 5 min on ice, followed by quenching with 10 mM dithiothreitol (DTT). Cross-linking
products were analyzed by reducing SDS-PAGE.
For puriﬁcation, TMEA-cross-linked capsid assemblies were disassembled by dialysis into disassembly
buffer (20 mM Tris-HCl, pH 8) at 4°C, and the cross-linking products were separated by size exclusion
chromatography on a Hi-Load Superdex 200 26/60 column equilibrated with disassembly buffer.
Reinjection of the trimer-containing fractions onto the size exclusion column yielded essentially pure
capsid trimers. Protein concentration was determined by UV absorbance using molar extinction coefﬁ-
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cients at 280 nm (280) of 33,524 M1cm1. Extinction coefﬁcients in this work are given for the protein
monomers.
Production of the HIV-1 capsid monomer, dimer, and hexamer. For the production of monomeric
HIV-1 capsid, the gene sequence encoding amino acids 133 to 278 of the HIV-1 Gag polyprotein,
comprising the NTD of HIV-1 capsid, was cloned into a pET20b vector with a C-terminal His6 tag,
cleavable by 3C protease. His-tagged HIV-1 capsid NTD was expressed as previously described (53) and
puriﬁed by immobilized-metal afﬁnity chromatography (IMAC) using Protino Ni-nitrilotriacetic acid
(Ni-NTA) agarose (Macherey-Nagel). Brieﬂy, E. coli cells expressing His-tagged HIV-1 capsid NTD sus-
pended in lysis buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM imidazole, 1 mM phenylmethylsul-
fonyl ﬂuoride [PMSF], 10 g/ml RNase A, 5 g/ml DNase I) were lysed using an EmulsiFlex C3
homogenizer (Avestin, Canada). The cleared lysate was loaded on an equilibrated Ni-NTA gravity column
and washed with 50 mM Tris-HCl (pH 8)–300 mM NaCl–40 mM imidazole, and bound protein was eluted
with 50 mM Tris-HCl–50 mM NaCl–300 mM imidazole. The C-terminal His tag was cleaved by the addition
of His-tagged 3C protease and dialysis against 50 mM Tris-HCl (pH 8)–50 mM NaCl–10 mM imidazole.
Untagged HIV-1 capsid NTD was then separated from the tag and the protease by another IMAC and
further puriﬁed by size exclusion chromatography on a Hi-Load Superdex 75 26/60 column equilibrated
with 20 mM Tris-HCl, pH 8.
The wild-type HIV-1 capsid dimer and the disulﬁde-linked A14C E45C W184A M185A HIV-1 capsid
hexamer were produced according to published procedures (38, 45).
Protein concentrations were determined using 280 values of 24,980 M1cm1, 33=524 M1cm1 and
28=210 M1cm1 for the HIV-1 capsid NTD monomer, the HIV-1 capsid dimer, and the disulﬁde-linked
HIV-1 capsid hexamer, respectively.
TEM analysis of capsid assemblies. Aliquots from capsid assemblies were diluted to 0.25 to 0.5
mg/ml, and 6-l samples were incubated on Formvar-coated copper grids for 30 s. The grids were
blotted, negatively stained three times on 20-l drops of 2% uranyl acetate for 10 s, blotted, and air dried.
Samples were imaged on a Philips CM 100 transmission electron microscope (TEM) at a magniﬁcation
of 13,000.
ESI-MS of cross-linked capsid trimers. Nanoelectrospray ionization mass spectrometry (nanoESI-
MS) analysis of the samples was performed on a Q-TOF Ultima API mass spectrometer (Micromass, United
Kingdom). The solutions were infused through a fused silica capillary (inside diameter [i.d.], 75 m) at a
ﬂow rate of 0.50 l min1. Electrospray Pico Tips (i.d., 30 m) were obtained from New Objective
(Woburn, MA). Mass spectra were acquired by scanning an m/z range from 500 to 2,500 with a scan
duration of 1 s and an interscan delay of 0.1 s. Spray voltage was set to 2.1 kV, cone voltage to 35 V, RF
lens 1 energy to 50 V, and collision to 10 eV. Before injection, the samples were desalted using C4-ZipTips
(Millipore) from which they were eluted with 10 l of 50:50:0.01 (vol/vol/vol) CH3OH:H2O:HCOH (pH 2).
Sedimentation velocity analytical ultracentrifugation. The oligomeric state of cross-linked capsid
proteins after puriﬁcation was veriﬁed by sedimentation velocity analytical ultracentrifugation (SV-AUC)
in 20 mM Tris-HCl, pH 8, at a protein concentration of 0.5 mg/ml. Sedimentation velocity measurements
were conducted at 30,000 rpm and 4°C using a ProteomeLab XL-1 ultracentrifuge (Beckman Coulter).
Data were analyzed with SEDFIT (54).
Production of recombinant TRIM B30.2 domains. DNA coding for the B30.2 domains of hsTRIM5
and rhTRIM5 (residues 286 to 493 and 288 to 497, respectively) was cloned into the pFXGST vector
using fragment exchange (FX) cloning (55). The pFXGST vector was generated by modiﬁcation of the
MultiBac vector pFBDM (56) multiple cloning site 1 (MCS1) to enable FX cloning in analogy to that
described by Weinert et al. (12). Brieﬂy, the SapI restriction site between the transposon element Tn7R
and the Col-E1 origin of replication was removed, and an NdeI restriction site was inserted into the MCS1
by QuikChange mutagenesis (Invitrogen). The FX cassette of the pBXGST vector (55) was used as the
template (including the coding region for an N-terminal His10 tag, followed by glutathione S-transferase
[GST] and a 3C cleavage site) and cloned into the modiﬁed pFBDM vector using NdeI and XbaI restriction
sites. The NdeI restriction site was later removed by QuikChange, yielding the pFXGST vector.
The TRIM B30.2 domains were expressed in Sf21 cells using the manufacturer’s protocol (Invitrogen).
Cells were harvested after 65 to 72 h of expression at 27°C and lysed in lysis buffer (50 mM Tris-HCl, pH
8, 300 mM NaCl, 10 mM imidazole, DNase I, RNase I, Benzonase, and EDTA-free complete inhibitor
cocktail [Roche Diagnostics]) using an EmulsiFlex homogenizer. Lysate was cleared, and the HisGST-
tagged TRIM B30.2 domain in the supernatant was puriﬁed by gravity-ﬂow IMAC as described above,
followed by overnight dialysis (Spectra/Por; 12,000 to 14,000 molecular weight cutoff [MWCO]) in
cleavage buffer (50 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.2 mM TCEP) at 4°C in the presence of a 1:20
(wt/wt) ratio of 3C protease. Cleaved HisGST tag and His-3C protease were removed by reapplying the
sample to Ni-NTA agarose. The ﬂowthrough was collected and concentrated to 2 mg/ml, as determined
by UV absorbance using a 280 value of 38,390 M1cm1 or 39,880 M1cm1 for the hsTRIM5 or
rhTRIM5 B30.2 domain, respectively.
The B30.2 domain of TRIM20 was prepared as described by Weinert et al. (57) and concentrated to
2 mg/ml (280  32,430 M1cm1).
Production of recombinant human cyclophilin A. The human cyclophilin A (CypA) gene was
cloned into the p7XC3H vector, which encodes a C-terminal 3C cleavage site and a His10 tag, using FX
cloning. The PCR primers were designed such that a Flag tag is encoded at the N terminus of the CypA
gene.
The CypA construct was expressed in E. coli Bl21(DE3). Cells were grown in 2 YT medium at 37°C
to an optical density at 600 nm (OD600) of 0.8, and expression was induced with 0.5 mM IPTG
(isopropyl--D-thiogalactopyranoside). Cells were harvested after 4 h of expression and lysed in 50 mM
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Tris-HCl (pH 8)–100 mM NaCl–0.5 mM TCEP–10 mM imidazole–1 mM PMSF–10 g/ml RNase A–5 g/ml
DNase I using an EmulsiFlex homogenizer. Lysate was cleared, and the supernatant was applied onto a
gravity-ﬂow IMAC column as described above. The His tag was cleaved overnight at 4°C by dialysis
(Spectra/Por; 6,000 to 8,000 MWCO) in the presence of 3C protease in 50 mM Tris-HCl, pH 8–100 mM
NaCl–0.5 mM TCEP–10 mM imidazole and removed by reapplying the sample to the IMAC column. As
a ﬁnal puriﬁcation step, the sample was applied to a Superdex 200 10/300 column equilibrated with 50
mM Tris-HCl (pH 8)–100 mM NaCl–0.5 mM TCEP–10% glycerol. Fractions containing Flag-tagged CypA
were pooled, concentrated to 2 mg/ml using an Amicon Ultra-15 concentrator (3,000 MWCO; Millipore),
and stored at 80°C. Protein concentrations were determined using a 280 of 9,970 M1cm1.
Fluorescent labeling of TRIM B30.2 domains and CypA. Puriﬁed B30.2 domains and CypA were
dialyzed (Spectra/Por; 6,000 to 8,000 MWCO) overnight at 4°C in labeling buffer (25 mM sodium
carbonate, pH 8.5, 100 mM NaCl, 0.5 mM TCEP). Labeling was carried out on ice in the presence of a
1.2-fold molar ratio of NT-647-NHS (Nanotemper) or Alexa Fluor 488-NHS (Alexa 488; Thermo Scientiﬁc)
by overnight incubation in the dark. At pH 8.5, labeling of the N-terminal amine (pKa 8) is favored over
the reaction with -amines of lysines (pKa 10.5). Therefore, modiﬁcation of lysines near the binding
interface is avoided at labeling efﬁciencies below one ﬂuorophore per B30.2 domain. Proteins were
separated from free dye by size exclusion chromatography on a Superdex 200 10/300 column. Coupling
efﬁciencies were calculated from the absorbances at 280 nm and 650/488 nm, respectively. The average
number of dyes per molecule ranged from 0.3 to 0.45. Tryptic digestion of labeled rhTRIM5 B30.2 and
matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) analysis of ﬂuorescent cleav-
age products after reversed-phase chromatography revealed a single peak corresponding to the
N-terminal B30.2 fragment GPSDMFR coupled to Alexa 488, conﬁrming the N terminus as the major site
of labeling.
MST. Twenty-ﬁve nanomolar concentrations of labeled B30.2 homologs were titrated with a 2:1
dilution series of the different capsid proteins. The samples were loaded into standard capillaries
(NanoTemper Technologies GmbH), sealed with soft wax, and equilibrated by incubation at 7°C for 4 h
before the measurement. Microscale thermophoresis (MST) measurements were carried out on a
NanoTemper Monolith NT.115 instrument (NanoTemper Technologies GmbH) using 40% LED and 20%
laser power with the laser switched on for 30 s, followed by an off period of 5 s. Fifteen or 16
thermophoresis measurements were carried out from three independently prepared dilution series.
Samples from each dilution series were recorded twice. The raw data were analyzed using the Nano-
Temper software to obtain binding curves. Kds were calculated with Prism (GraphPad Software) by ﬁtting
the data with a 1:1 binding isotherm equation:
fb capsid ⁄ Kd capsid (1)
where fb is the fraction of bound B30.2 domain, [capsid] is the capsid concentration, and Kd is the
dissociation constant. The MST experiments were carried out at 7°C, because higher capsid concentra-
tions could be achieved without aggregation. To rule out effects of temperature on the binding afﬁnity,
measurements at 7°C and room temperature were compared, and very similar afﬁnities were obtained
(Fig. 5a).
2fFCS. For dual-focus ﬂuorescence correlation spectroscopy (2fFCS) measurements (44), a capsid
dilution series such as that described for MST was prepared with Alexa 488-labeled TRIM5 B30.2 and
CypA at a ﬁnal concentration of labeled protein of 2 nM. CypA was included as a reference to quantify
the contribution of viscosity to the measured diffusivity. CypA is suitable as a reference for several
reasons. First, it has a similar molecular mass (19 kDa for Flag-CypA) and shape as rhTRIM5 B30.2 (23
kDa) and therefore a similar hydrodynamic radius (Rh). Second, CypA and the B30.2 domain occupy
overlapping binding surfaces on the capsid (26, 29–33), so their respective capsid complexes should also
have similar Rh values. Third, CypA has a relatively high afﬁnity for the HIV-1 capsid surrogates (see Table
1), so binding occurs in a concentration range that is well separated from viscosity effects, which start
to interfere with the measurements at capsid concentrations above 100 M (Fig. 7). After completion
of the 2fFCS measurement, the capsid concentration in each sample was determined via absorbance at
280 nm.
The measurements were carried out at 7°C on a confocal single-molecule instrument (MT200;
PicoQuant), equipped with a differential interference contrast prism (U-DICTHC; Olympus). The sample
was excited alternatingly with two orthogonally polarized diode lasers at 485 nm (LDH-D-C-485;
PicoQuant) with a repetition rate of 40 MHz and a laser power of 30 W each. The distance, d, of 436 
10 nm between the two foci in aqueous solution was determined by measuring a series of reference
samples with a known diffusion coefﬁcient (58). A custom-built temperature-controlled sample holder
was used to cool the sample cell. The microscope objective was cooled as well to minimize the
temperature gradient between sample cell and objective.
The ﬂuorescence intensity cross- and autocorrelation curves obtained from the data of each focus
were analyzed using a custom-written C routine and Mathematica (Wolfram Research) to obtain
diffusion coefﬁcients, D (59). These were converted to hydrodynamic radii, Rh, with the Stokes-Einstein
relation Rh kBT/(6	D), where kB is the Boltzmann constant, T is the temperature, and 	 is the viscosity
of the solution. The increase in apparent Rh of the labeled molecules upon binding to capsid was
analyzed with a simple stoichiometric binding model multiplied with a correction term for the increased
viscosity at high capsid concentrations.
Rh Rh,0 Rh,end
 Rh,0 · capsidKd capsid  · 	[capsid]	0 (2)
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In a ﬁrst step, the CypA data set was ﬁtted to extract the hydrodynamic radius of the unbound
molecule (Rh,0), the hydrodynamic radius of the capsid complex (Rh,end), the dissociation constant (Kd),
and the capsid concentration-dependent viscosity contribution 	[capsid] empirically approximated by
	[capsid]  	0 (1  [capsid], with 	0 being the buffer viscosity,  adjusted in the range of 1.5 to 2 to ﬁt
the data, and [capsid] in M). The binding of capsid to CypA is largely saturated before the sample
viscosity starts to increase signiﬁcantly, so the contributions of binding and viscosity to the increase in
Rh can be separated (Fig. 7a to c). For ﬁtting the TRIM5 B30.2 2fFCS data, the parameters Rh,0, Rh,end, and
	[capsid] were ﬁxed to the values extracted from ﬁtting the CypA data set, so Kd was the only free ﬁt
parameter. For comparison with the MST data, Rh was converted to the fraction of bound B30.2
domain/CypA, fb, according to the equation:
fb  Rh	0	[capsid] 
 Rh,0 ⁄ Rh,end
 Rh,0 (3)
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